Neuroscience News

New research shows aging is not a uniform process. Parts of our bodies start aging earlier than others, right down to our organs and cells.

With Knight Initiative support, Stanford researchers uncover a biochemical “off-ramp” in ketosis, rewriting our understanding of how ketosis influences metabolism.

The Knight Initiative for Brain Resilience supports 14 high-risk, high-reward projects to advance brain health and resilience research, fostering bold research across various scientific disciplines.

This week on From Our Neurons to Yours, we talk with Stanford neurologist Mike Greicius about his critique of new amyloid-clearing Alzheimer's drugs, and his optimism for the next wave of therapies currently in development.

Study in mice, supported by the Knight Initiative, suggests that an experimental cancer drug boosted brain metabolism, restored memory, and improved Alzheimer's symptoms. This novel approach may offer a new way to treat Alzheimer's beyond targeting amyloid plaques.

Sergiu Pașca has figured out how to watch the human brain develop in real time. Next up: revolutionizing psychiatry.

The APOE4 genetic variant, carried by about 20% of people, significantly raises Alzheimer’s risk. But should we boost the gene’s potency or suppress it? A recent discovery by Knight Initiative affiliate, Mike Greicius, may provide the answers we need.

A team of neuroscientists at the Knight Initiative for Brain Resilience have zeroed in on a critical regulator of brain metabolism that may be over-activated in the brains of patients with Alzheimer’s disease.

Groundbreaking research supported by the Knight Initiative for Brain Resilience at Stanford’s Wu Tsai Neurosciences Institute deepens our understanding of how the amino acid taurine may help reduce appetite and prevent obesity.

The Knight Initiative's Year-End Symposium and Research Showcase featured a wide range of promising new approaches to understanding brain aging, resilience, and neurodegeneration.

The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease, but which also carry safety risks according to Knight Initiative for Brain Resilience Affiliate Mike Greicius and others.

This week, we talk with Michelle Monje and Rob Malenka about recent findings on the role of myelin plasticity in opioid addiction.

Why do our brains get worse at learning as we get older, and what can we do about it? Institute affiliate Carla Shatz discusses our brain's capacity for change on this podcast episode.

Most Parkinson’s disease patients struggle with speech problems. New research by Stanford Medicine scientists uncovers the brain connections that could be essential to preserving speech.

This week, we talk with Surya Ganguli about the neuroscience of AI, and how advances in artificial intelligence could teach us about our own brains.

This week on From Our Neurons to Yours, we talk with memory expert Anthony Wagner about the nature of memory and how to improve it.